Vertex announces European Commission approval for Kalydeco to treat infants with cystic fibrosis ages 1 month and older

26 April 2024 - Kalydeco is the first and only medicine approved in the EU in this age group to ...

Read more →

FDA grants Medivir´s MIV-711 rare paediatric disease designation and orphan drug designation for the treatment of Legg-Calvé-Perthes Disease

25 April 2024 - Medivir announced today that its selective cathepsin K inhibitor, MIV-711, has been granted rare paediatric disease designation ...

Read more →

Children and teenagers with an aggressive form of brain cancer set to benefit after NICE recommends new life-extending drug combination treatment

24 April 2024 - A new targeted drug combination treatment, described as a ‘step-change in care’ for children and young ...

Read more →

FDA grants accelerated approval to tovorafenib for patients with relapsed or refractory BRAF altered paediatric low-grade glioma

23 April 2024 - Today, the FDA granted accelerated approval to tovorafenib (Ojemda, Day One Biopharmaceuticals) for patients 6 months ...

Read more →

FDA approves lutetium Lu 177 dotatate for paediatric patients 12 years and older with GEP-NETs

23 April 2024 - Today, the FDA approved lutetium Lu 177 dotatate (Lutathera, Advanced Accelerator Applications) for paediatric patients 12 ...

Read more →

Fasenra approved for treatment of children aged 6 to 11 with severe asthma

11 April 2024 - AstraZeneca’s Fasenra (benralizumab) is now approved by the US FDA for add-on maintenance treatment for patients ...

Read more →

ViiV Healthcare announces US FDA approval of Dovato (dolutegravir/lamivudine) for adolescents living with HIV

8 April 2024 - Dovato is now the first and only oral, two drug, single-tablet regimen available for people aged 12 ...

Read more →

Solid Biosciences receives rare paediatric disease designation from the FDA for Duchenne muscular dystrophy gene therapy candidate SGT-003

1 April 2024 - Site initiations scheduled for April; patient dosing expected to begin in Q2 ,2024. ...

Read more →

FDA Approves Medexus's supplemental biologics license application for Ixinity to treat haemophilia B in paediatric patients

26 March 2024 - Expanded indication includes patients under 12 years of age, based on Phase 3/4 data demonstrating safety and ...

Read more →

Paladin Labs announces approval of Wakix (pitolisant hydrochloride tablets) for use in paediatric patients in Canada

28 March 2024 - Indication includes children ages 6 years and older and weighing at least 30 kg. ...

Read more →

Beyfortus approved in Japan for the prevention of RSV disease in infants

27 March 2024 - First and only RSV preventive option for broad infant population authorised for use in Japan. ...

Read more →

Tonix Pharmaceuticals receives rare paediatric disease designation from the FDA for TNX-2900 for the treatment of Prader-Willi syndrome

25 March 2024 - TNX-2900 is a proprietary magnesium-potentiated formulation of intranasal oxytocin, a naturally occurring hormone that reduces appetite and ...

Read more →

FDA grants Argenica rare paediatric disease designation for ARG-007 in the treatment of HIE

25 March 2024 - Argenica Therapeutics is pleased to announce the US FDA has granted its neuroprotective drug ARG-007 rare ...

Read more →

Lisata Therapeutics announces US FDA rare paediatric disease designation granted to LSTA1 for the treatment of osteosarcoma

21 March 2024 - Lisata Therapeutics today announced that the US FDA has granted rare paediatric disease designation to LSTA1, the ...

Read more →

A lifesaving therapy for children with a rare disease is now the world’s most expensive drug, raising questions about access

20 March 2024 - A new gene therapy for the fatal genetic disorder metachromatic leukodystrophy, or MLD, will carry a ...

Read more →